+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
ContraFect Corporation is a biotechnology company that develops therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.